Abstract
Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.
Keywords: Artemisinin, malaria, quinine, treatment.
Infectious Disorders - Drug Targets
Title:Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Volume: 13 Issue: 4
Author(s): Philip Botha, Emmanuel Bottieau, Olalekan Uthman, Ude Obike and Jean B. Nachega
Affiliation:
Keywords: Artemisinin, malaria, quinine, treatment.
Abstract: Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.
Export Options
About this article
Cite this article as:
Botha Philip, Bottieau Emmanuel, Uthman Olalekan, Obike Ude and Nachega B. Jean, Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations, Infectious Disorders - Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/1871526513666140103122630
DOI https://dx.doi.org/10.2174/1871526513666140103122630 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including their Transporters
Current Topics in Medicinal Chemistry Structural and Functional Characterization of a γ-Type Phospholipase A2 Inhibitor from Bothrops jararacussu Snake Plasma
Current Topics in Medicinal Chemistry Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Microwave Assisted Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Prolonged Physiologic Doses of Corticosteroids for the Treatment of Severe Community Acquired Pneumonia
Current Respiratory Medicine Reviews Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets Chromogranin A as a Calcium-Binding Precursor for a Multitude of Regulatory Peptides for the Immune, Endocrine and Metabolic Systems
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Strategies to Avoid TAVI-related Acute Kidney Injury
Current Pharmaceutical Design